SUPPLEMENTARY MATERIAL
The cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial Violato M, Dakin Other  administrative  staff  Less than £20,000  4  5  24  14  3  10  £20,000 to £29,999  2  0  4  2  5  2  £30,000 to £39,999  9  0  0  0  6  0  £40,000 to £49,999  9  0  0  0  0  0  £50,000 to £59,999  10  0  0  0  0  0  £60,000 to £69,999  4  0  0  0  0  0  £70,000 to £79,999  1  0  0  0  0  0  £80,000 per year or  more   1  0  0  0  0  0   Observations  40  5  28  16  14  12 Supplementary a So as to not overburden participants the health economics questionnaire was not a compulsory section for participants, which reduced the number of returned questionnaires to 40 out of the 61 questionnaires initially sent out to optometrists. b So as to not overburden participants the feed-back questionnaire was not a compulsory section for participants, which reduced the number of returned questionnaires to 55 out of the 61 questionnaires initially sent out to optometrists.
Seven percent of data from the completed questionnaires were missing, although the majority of missing data were associated with tasks for which many optometrists may have limited experience (e.g. conducting colour fundus photography, OCT or updating medical records). Given the structure of the dataset, it would have been extremely difficult to conduct multiple imputation and this would have added additional complexity into the assignment of costs. We therefore used mean imputation to allow for missing data, following the approach used to cost up consultations in the IVAN trial [3] . 
Supplementary

COST MODEL -RANDOM ALLOCATION
Following the methods adopted in the IVAN trial, we randomly sampled from the distribution of costs from different optometrist practices using the following procedure: -A weight was assigned to each practice based on the number of patients they could accommodate monthly, after any necessary changes to their practice are implemented, divided by the total number of all patients with quiescent nAMD that could be accommodated by all the practices in the study. Cumulative weights were then calculated and assigned to each optometric practice. -For each vignette (potential patient) a random number was generated. This random number determined which of the monitoring review costs each vignette (i.e. each potential patients) was randomly assigned to according to the following decision rule: if the random number assigned to the first vignette (potential patient) was X and the weight assigned to the first optometry practice was A and the weight assigned to the second optometry practice was B, the vignette was assigned the cost from the first optometry practice if X<A and was assigned the cost for the second practice if A<X<A+B. -All the monitoring consultations associated to that vignette (potential patient) were valued at the price for that monitoring review.
In this way, for each vignette (potential patient) addressed by a community optometrist, we randomly drew a value for the cost of the community optometry review from the distribution of ECHOES monitoring review costs; for each vignette addressed by an ophthalmologist, we randomly drew a value for the cost of a hospital review from the cost distribution used in IVAN. For those vignettes where a wrong decision results in an additional hospital monitoring consultation, or an injection, we drew additional random numbers to sample those consultation costs from the distribution of costs as reported in IVAN. 
ADDITIONAL FIGURE ON THE BASE CASE ANALYSIS
SENSITIVITY ANALYSES
Sensitivity analyses were conducted to explore the effect of varying the way of delivering treatment for lesions assessed as reactivated, which is one of the main cost drivers in our analysis. In the base case analysis, it was assumed that treatment for an active lesion consisted of one ranibizumab injection given during an injection consultation.
Sensitivity Analyses 1, 2, and 3
In our first three sensitivity analyses, one ranibizumab injection was replaced with alternative treatments to reflect different practice across eye hospitals (sensitivity analyses 1 and 2) and to make a comparison with a much cheaper drug assessed in the IVAN trial (sensitivity analysis 3). More specifically: -Sensitivity analysis 1: treatment for an active lesion was assumed to be a course of three injections of ranibizumab at three subsequent injection consultations, with no additional monitoring reviews; -Sensitivity analysis 2: treatment for an active lesion was assumed to be given in the form of one aflibercept injection during an injection consultation; -Sensitivity analysis 3: treatment for an active lesion consisted of one bevacizumab injection given during an injection consultation. Tables A.5 , A.7, and A.9), cost-effectiveness of a monitoring review performed by optometrists versus a monitoring review performed by ophthalmologists Figures A.3 , A.5, and A.7), are reported below for each of the three sensitivity analyses. Similar to the base case analysis, optometrist-led monitoring reviews remained dominated by ophthalmologist-led reviews, and there was no acceptable willingness-to-pay threshold for which we can be 95% confident that the two alternative ways of performing a monitoring review differ in value. 
Care pathway costs (Supplementary
Results of sensitivity analysis 1: Course of 3 ranibizumab injections
Supplementary
Sensitivity analysis 4
This sensitivity analysis considers only the cost of a monitoring review rather than considering the cost of the whole pathway (Supplementary Table A.11). As Supplementary Table A.12 shows, this analysis finds optometrist-led care to be less effective and significantly less costly than ophthalmologist-led care. Ophthalmologist-led care costs £2389 per additional correct treatment decision compared with optometrist-led care. Even though the maximum amount the NHS is willing to pay for a correct retreatment decision is unknown, it is unlikely to be so high as £2389, which would suggest that optometrist-led care is good value for money if you focus exclusively on the cost of the initial monitoring consultation and ignore downstream costs. As shows, at ceiling ration of £600 or lower, we can be 95% confident that optometrists are a cost-effective option compared with ophthalmologist in this fourth sensitivity analysis. This result emphasises the importance of building a simple decision model to explore the consequences after the initial monitoring review, rather than using only the information from the initial review. Furthermore, it also indicates that the conclusions of the analysis may be sensitive to the assumptions within the decision tree. 
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Sensitivity Analysis 5
This sensitivity analysis consisted in modifying the base-case scenario to account for a different 'care pathways model' and associated costs. In particular, whenever the optometrist's judgment was 'reactivation', we assumed that the OCT images taken by the optometrist would be further analysed by an ophthalmologist with the aim to confirm or not the optometrist's assessment. In the base-case analysis the assumption was instead that the patient would have undergone another full monitoring visit at the eye hospital prior to treatment. Based on the expert opinion of the clinicians in the ECHoES trial team, the average duration of this further ophthalmologic check was set to 16.5 minutes. The associated cost was estimated based on the hourly rate of ophthalmologist's time as reported in the IVAN trial [3] , and added to the cost and cost-effectiveness analyses.
Supplementary Table A.13 below shows that when optometrists correctly judge the lesion as 'reactivated', the average pathway cost for optometrists is lower than in the base case analysis (see Table 1 in the main article), because in this new care model we have assumed that patients do not need to be referred for another complete monitoring review at the hospital eye clinic before actually receiving treatment, but instead it will suffice for the ophthalmologist to review the OCT images taken by the optometrist to assess the accuracy of the optometrist's judgement. Similarly, when vignettes are truly suspicious/quiescent and optometrists assess the lesion as 'reactivated', the average pathway cost for optometrists is lower than the corresponding value in the base case analysis. When the new care pathway model is used, in conjunction with health outcomes, to investigate the cost-effectiveness of a monitoring review performed by optometrists versus a monitoring review performed by ophthalmologists, the results are overall in line with what already found for the base case scenario (see Table 1 in the main article). Once again, in fact, we find a situation in which no statistically significant difference is observed either in costs or effects.
Supplementary Table A.14 below shows that the differences in costs and in effects between the two professional groups are still small and not statistically significant, but the optometrist-led reviews now decrease the total costs by £8.61 per review (in the base case-scenario there was an increase of £13): a decrease of 2% of the total cost of the care pathway (vs. a 3% increase in the base case scenario). As in the base case scenario, optometrist-led reviews result in only one more incorrect decision per 101 monitoring reviews conducted. As result, in this scenario optometrist-led care would save £870 every additional incorrect retreatment decision. In other words, ophthalmologists-led monitoring reviews costs an additional £870 per correct re-treatment decision compared with optometrist-led care. Referring patients to receive monitoring at community optometry practices is therefore cost-effective if the NHS is willing to accept one additional incorrect retreatment decision in order to save £870.
In this new sensitivity analysis, there is still substantial uncertainty around the finding, as in the base case scenario. The CEAC in Supplementary Figure A .5 below finds a much higher probability that optometrist-led monitoring reviews are cost-effective. If the NHS is willing to pay £200 per correct retreatment decision, the probability that it is cost-effective to conduct monitoring by community optometrists is 68.5% (the corresponding probability in the base-case scenario was 14%), which decreases to a probability of 58% if the NHS were willing to pay £600 per correct decision (the corresponding probability in the base-case scenario was 8%). As the willingness to pay threshold increases, the probability that optometrist-led reviews are cost-effectiveness steeply decreases, then stabilises at around 30% for willingness to pay values higher than £5000. Since the difference in cost between monitoring reviews conducted by optometrists and ophthalmologists was not statistically significant, we can be no more than 70% confident that optometrist-led and ophthalmologist-led care is cost-effective. However, this analysis nonetheless suggests that optometrist-led monitoring reviews would be cost-effective compared with ophthalmologist-led reviews if the HES relied upon re-review of the OCT images taken by optometrists, rather than conducting an additional monitoring review for all patients referred by optometrists. Incremental benefit, percentage of correct assessments (95% CI) -1.0% (4.5%, 2.5%) 1 The 95% CI around the ICER could not be defined 
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.(please fill in)
Thank you for taking time to complete this questionnaire. Your answers will be kept confidential and used only for the ECHoES study.
One component of the ECHoES study is to provide the NHS with information on how cost-effective it is for optometrists to perform retreatment assessments for patients with quiescent neovascular agerelated macular degeneration (nAMD).
In order to do this we would like you to answer, to the best of your knowledge, the following questions about any resources and costs that would be associated with providing this new service in optometric practices.
Notes on questionnaire completion:
• If you do not know the answer to any given question, please give your best guess wherever possible and otherwise leave it blank and complete the rest of the questionnaire.
• Please write "0" in response to any questions to which the answer is zero.
• All costs should include VAT whenever applicable.
• Questions will be reported in Italics, while explanatory text to set the background to the question will be reported in normal font.
If you have any questions regarding this questionnaire please contact: Dr Mara Violato (mara.violato@dph.ox.ac.uk; Tel 01865 289265) or Dr Sarah Wordsworth (sarah.wordsworth@dph.ox.ac.uk; Tel 01865 289268) ****************************** Set up/ Capital and operative costs ****************************** Imagine that the community optometric practice where you work is going to be involved in shared care-management for monitoring the need for retreatment of patients with nAMD whose disease has been rendered quiescent by anti-VEGF drugs, such as Avastin or Lucentis. We would like to know which facilities the practice already has and which facilities need to be set up in order to be able to offer this new monitoring service.
When answering, please keep in mind that the appointment for monitoring will typically consist of the components and skills summarised in Table 1 The results will then be recorded in the patient medical record.
Test and interpret visual acuity
Administration of 1% tropicamide drops Pupil dilation. Drops will need to be administered 20 minutes before colour fundus photography and spectral domain coherence tomography.
Instillation of eye drops
Colour fundus photography (or equivalent colour fundus image)
One good quality photograph centred on the centre of the macula of each eye.
Taking and interpreting retinal images
Spectral domain optical coherence tomography (OCT)
Cube scan of the posterior pole for each eye. Images will be acquired using a standardised protocol, which is pre-set on the OCT machine.
Taking and interpreting OCT images
Final assessment A retreatment decision will be made on the basis of the visual acuity data and interpretation of images obtained.
The decision and rationale will need to be entered in the patient record.
Ability to assess the need for retreatment and arrange necessary follow-up Q1. Given the above description, how long do you think each monitoring review will take? Please include in your estimate the 20 minutes that the patient will have to wait for the dilating drops to work.
…..minutes
As optometric practices are very heterogeneous, we would first like to have a sense of such diversity in order to plan a shared-care programme that accounts for the needs of all practices. We would therefore like you to describe your practice by replying to the following questions. N.B. If you own/work in more than one practice, please reply to the whole questionnaire referring only to the practice where you spend most of your time. 
Q2.
